All Mallinckrodt Pharmaceuticals articles

  • Pharmaceuticals

    Compliance ramifications of proposed $26B opioid deal for pharma industry


    Three major drug distributors and drugmaker Johnson & Johnson reached a proposed $26 billion multistate agreement for their alleged roles in fueling the nationwide opioid epidemic. The settlement imparts compliance lessons on the pharmaceutical industry at large.

  • McKinsey

    McKinsey to pay $573M for role in opioid epidemic


    McKinsey & Company reached a $573 million settlement with 49 state attorneys general and the District of Columbia related to consulting services it provided to pharmaceutical companies that directly contributed to the opioid epidemic.

  • Pharmaceuticals

    DOJ intervenes in whistleblower suit against Mallinckrodt


    The Department of Justice has intervened in a whistleblower lawsuit against Mallinckrodt over allegations the drug maker knowingly underpaid Medicaid rebates it owed due to significant price increases to its drug Acthar.

  • oxy_450x200_-_homepage

    The compliance side of the war on drugs


    In a precedent-setting case, drugmaker Mallinckrodt Pharmaceuticals has agreed to a $35 million settlement with the U.S. federal government for failing to monitor its sales channels for suspicious orders.